The tuberculin skin test (TST) is still the standard test for detecting latent infection by M tuberculosis (LTBI). Given that the Brazilian Health Ministry recommends that the treatment of latent tuberculosis (LTBI) should be guided by the TST results, the present study sets out to describe the coverage of administering the TST in people living with HIV at two referral health centers in the city of Recife, where TST is offered to all patients. In addition, factors associated with the non-application of the test and with positive TST results were also analyzed.
Methods
A cross-sectional study was carried out with HIV patients, aged 18 years or over, attending outpatient clinics at the Correia Picanço Hospital/SES/PE and the Oswaldo Cruz/UPE University Hospital, who had been recommended to take the TST, in the period between November 2007 and February 2010. Univariate and multivariate logistic regression analyses were carried out to establish associations between the dependent variable - taking the TST (yes/no), at a first stage analysis, and the independent variables, followed by a second stage analysis considering a positive TST as the dependent variable. The odds ratio was calculated as the measure of association and the confidence interval (CI) at 95% as the measure of accuracy of the estimate.
Results
Of the 2,290 patients recruited, 1087 (47.5%) took the TST. Of the 1,087 patients who took the tuberculin skin test, the prevalence of TST ≥ 5 mm was 21.6% among patients with CD4 ≥ 200 and 9.49% among those with CD4 < 200 (p = 0.002). The patients most likely not to take the test were: men, people aged under 39 years, people with low educational levels and crack users. The risk for not taking the TST was statiscally different for health service. Patients who presented better immunity (CD4 ≥ 200) were more than two and a half times more likely to test positive that those with higher levels of immunodeficiency (CD4 < 200).
Conclusions
Considering that the TST is recommended by the Brazilian health authorities, coverage for taking the test was very low. The most serious implication of this is that LTBI treatment was not carried out for the unidentified TST-positive patients, who may consequently go on to develop TB and eventually die.
Background
The HIV epidemic has had serious consequences around the world and especially in developing countries. One of the gravest of these has been an increase in the incidence of tuberculosis (TB) [1]. In the population not infected with HIV, 5% of those infected with M. tuberculosis may develop primary TB within the first two years following exposure and another 5% may develop post-primary TB later in life. By contrast, co-infected individuals stand a 5-10% chance each year of developing TB [2, 3].
In recent years, considerable investment has been made available for research into tuberculosis control programs, including the introduction of various strategies to contain the advance of this epidemic [1, 4, 5]. However, despite the adopted strategies, there has been an increase in the prevalence of HIV, which has resulted in a rise in the incidence of TB [6]. Tuberculosis is still the leading cause of death in HIV positive patients in various parts of the world, especially in countries where the disease is rife and resources are limited [7–9].
Clearly, the risk of developing TB is lower in patients infected with HIV who receive HAART. However, TB still occurs even when patients are undergoing HAART [8, 10–13]. In countries with a low prevalence of TB/HIV co-infection the use of HAART is associated with a marked reduction in the incidence of many opportunistic infections [10, 14–16], while in countries with a high prevalence of co-infection it is still unclear whether this protective effect occurs [17]. To establish a substantial impact on the incidence of TB, it would be necessary to begin HAART early in the course of HIV infection, with a high level of coverage and adherence [18].
The effectiveness of LTBI treatment with isoniazid in people living with HIV has been reported since the last decade. The majority of clinical trials and prospective cohort studies have shown that treatment with isoniazid for six or 12 month periods prevents tuberculosis and is safe in people infected with HIV and with TST ≥ 5 mm [19–25]. Based on the existing evidence, LTBI treatment with daily doses of isoniazid for six or nine months is recommended in individuals living with HIV [26, 27].
HIV positive patients with a reactive TST (≥ 5 mm) have a significantly higher risk of developing full-blown TB than those who do not react (< 5 mm) [28–30]. A systematic review of randomized clinical trials shows that the treatment of LTBI based on a reactive TST reduces the risk of active TB in patients with HIV [31]. Evidence such as this provides grounds for the use of TST and the subsequent treatment of LTBI [32, 33].
The tuberculin skin test (TST), based on the detection of a delayed hypersensitivity reaction to Purified Protein Derivative (PPD) is still the standard test for detecting infection by M. tuberculosis. In order to conduct this test, two visits are needed, one for the inoculation and another to read and interpret the test results [32, 33], Although it is a simple test requiring only low-cost materials, with no need for the presence of a laboratory specialist and is extensively used in contexts where resources are limited, epidemiological studies and annual investigations [34, 35] have nonetheless shown that there are practical difficulties associated with administering the TST. Coverage differences exist for administering the TST in different health services, suggesting that the motivation of health staff is important when caring for HIV-positive patients [28]. On the other hand, the low sensitivity and specificity of the TST has cast some doubt on its performance and, as a consequence, it has been less requested by attending physicians [12, 28]. There is also concern that LTBI treatment using isoniazid alone may lead to resistance to this drug [36, 37] as well as potential side-effects [24, 38, 39]. However, TST is still used worldwide for LTBI screening in individuals with HIV/AIDS, including developing countries [40].
From a clinical perspective, the diagnosis and treatment of LTBI are important measures in reducing the risk of progression to active TB and its associated complications [6]. It is believed, that where an effective logistical system for acquiring and distributing the TST and isoniazid (INH) was established, both physicians and patients would be encouraged to take the TST and read the results [17, 26, 41].
Given that the Brazilian Health Ministry recommends that LTBI treatment should be guided by the results of the TST [42–44] the present study aims to describe the coverage of administrating the TST in people living with HIV/AIDS, attended at two health centers in the city of Recife, where TST is available. In addition the factors associated with the non-application of the test, and with a positive TST result in patients infected with HIV, were also analyzed.
Methods
Study Population, Recruitment, and Survey Methods
A cross-sectional study was carried out with people living with HIV/AIDS, aged 18 years or over, attending outpatient facilities at the Correia Picanço Hospital/SES/PE and the Oswaldo Cruz/UPE University Hospital, which are referral services for HIV/AIDS in the city of Recife, Brazil, between November 2007 and February 2010.
Patients were excluded if they had a previous history of or were undergoing treatment for tuberculosis or LTBI.
Patients were first informed of the purpose of the research and, once they had agreed to participate, were asked to sign the terms of free informed consent. Information was gathered by way of interviews and the application of a questionnaire designed specifically for this study. In addition to the questionnaire, a special form was used by the principal researcher to obtain data from medical records.
The tuberculin skin test was carried out by trained technicians at each health center, using the Mantoux technique. A 0.1 ml dose of PPD (purified protein derivative) RT 23, was applied intradermally in the middle third of the left forearm. The test was considered to be reactive when an induration ≥ 5 mm was detected, 72 hours after administering the PPD.
In view of the known difficulty of incorporating this test into clinical practice, the research plan included a lecture for attending physicians, at each of the services covered by the study. The talk was delivered by a specialist in pneumology with extensive experience in tuberculosis, in an attempt to raise awareness among physicians of the importance of performing the TST and treating LTBI, when recommended, in patients with HIV/AIDS. Talks were also arranged for patients at the two centers as a way of informing them of the risk of contracting TB and of the importance of the TST in screening for LTBI.
The study was carried out in two stages. In the first stage, involving all the patients in the cohort making up the study sample, the coverage of TST testing was calculated and factors associated with not taking the test were investigated; in a second stage factors associated with testing positive on the TST were analyzed only for the group of patients who actually took the test.
Definition of Variables
In the first analysis, the dependent variable was having taken the tuberculin skin test, considering patients who did not take the TST as cases and those who did as the control group.
The independent variables examined were: biological variables (sex and age), socio-demographic factors (place of residence, years of schooling, hospital attended), life habits (alcohol consumption - categorized as abstinent, light drinker, heavy drinker, and people undergoing alcohol dependence treatment -, smoking - categorized as non-smoker, former smoker, and smoker -, marijuana use, cocaine use, and crack use) and clinical variables (history of contact with tuberculosis, body mass index (BMI), use of HAART, time on HAART, presence of AIDS, CD4 T-lymphocyte count)
For the alcohol consumption variable, patients were classified as teetotal if they reported that they never drank or drank less than eight units a year; a light drinker if they drank a maximum of two days a week, without exceeding ten units per month; a heavy drinker if they drank in excess of five doses a day at least 3 to 4 days a week, and as dependent if they were undergoing treatment. For the smoking variable, non-smokers were considered to be those who had never smoked in their life, former smokers those who had quit smoking at least six months before the date of inclusion in the study; and smokers those who were smoking on the day they entered the study or who had quit less than six months before this date.
In the second analysis, the dependent variable relating to the result of the tuberculin skin test was classified on the basis of patients who reacted to the TST (≥ 5 mm) and the controls, which did not react (0-4 mm). The independent variables were the same used for the first stage.
Data Analysis
For both stages of the study, the χ2 test was used to test the statistical significance of associations and the p value was calculated. A univariate analysis was conducted of the association between the dependent variable and the independent variables, using the odds ratio (OR) as the measure of association (OR) and a confidence interval (CI) of 95% as the measure of accuracy of the estimate. Analysis of multivariate logistic regression used the backward stepwise method for selecting variables, thereby including in the model all variables associated with failure to conduct the tuberculin skin test for the first stage, and with a positive TST for a second stage, with a level of significance of p < 0.25 in the univariate analysis. The final model retained variables whose association with failure to conduct the TST for the first stage, and with a positive TST for a second stage were statistically significant at a level of p ≤ 0.05.
The study was approved by the Ethics Committee at the Federal University of Pernambuco for research involving human beings (SISNEP FR-067159/CAAE-0004.1.172.106-05/REGISTRO CEP/CCS/UFPE 254/05).
Results
Between November 2007 and February 2010, 2,290 patients were recruited for the study. Of these, 1,425 (62.2%) were male and the mean age of the patients was 39.36 years. Most of the patients included in the study were non-white (73.4%), lived as part of a family (80.8%) and did not have a steady partner (53.5%). 87.8% were literate and 58.6% had up to nine years of schooling. In relation to life habits, 38.3% consumed alcohol, 27.3% used marijuana, 9.2% cocaine, 6.9% crack and 55.1% were smokers.
A total of 641(28%) patients related contact with tuberculosis, while information on close contact with smear positive TB was unavailable.
Of the 2,290 patients, 1087 (47.5%) took the tuberculin skin test (TST) (Figure 1). The mean age of the group who took the TST was 40.4 years (± 0.3) compared with 38.4 years (± 0.3) for the group who did not. The difference between these two means was not statistically significant. Tables 1 and 2 show the percentage distributions for the variables studied, chi square and p value.
Figure 1
Flowchart of the study population.
Table 1
Distribution of biological and socio-economic characteristics of people living with HIV by adherence to TST and TST reactivity, Recife 2007-2010.
Distribution of habits and clinical characteristics of people living with HIV by adherence to TST and TST reactivity, Recife 2007-2010.
VARIABLES
WITH TST
WITHOUT TST
Chi2
Pr
TST ≥ 5 mm
TST = 0-4 mm
Chi2
Pr
n
%
n
%
n
%
n
%
Habits
Alcohol Consumption
0.3
0.591
3.9
0.048
Non-drinker
665
61.2
666
62.3
123
55.4
542
62,7
Drinker
422
38.8
403
37.7
99
44.6
323
37.3
Smoking
2.5
0.113
7.6
0.006
No
506
46.6
519
43.2
85
39.3
421
48.7
Yes
581
53.4
681
56.8
137
61.7
444
51.3
Marijuana Use
7.6
0.006
12.8
< 0.001
No
820
75.4
842
70.3
147
66.2
673
77.8
Yes
267
24.6
356
29.7
75
33.8
192
22.2
Crack use
8.5
0.003
20.3
< 0.001
No
1030
94.80
1099
91.7
197
88.7
833
96.3
Yes
57
5.20
100
8.3
25
11.3
32
3.7
Cocaine use
7.2
0.007
5.9
0.015
No
1006
92.50
1070
89.3
197
88.7
809
96.5
Yes
81
7.50
128
10.7
25
11.3
56
6.5
Clinical variables
History of Contact with Tuberculosis
1.8
0.174
2.3
0.133
No
762
70.5
873
73.1
146
66.4
616
71.5
Yes
319
29.5
322
26.9
74
33.6
245
28.5
BMI
12.7
< 0.001
0.5
0.492
Not malnourished
1010
93.1
997
88.7
209
94.1
803
92.8
Malnourished
75
6.9
127
11.3
13
5.9
62
7.2
On HAART
0.0
0.918
4.9
0.026
No
240
22.2
246
22.3
61
27.7
179
20.7
Yes
843
77.8
855
77.7
159
72.3
684
79.3
Time on HAART
38.8
< 0.001
2.8
0.096
Less than 1 year
139
12.8
202
23.3
21
9.5
118
13.6
One year or more
948
87.2
653
76.3
201
90.5
747
86.4
AIDS
24.7
< 0.001
2.9
0.087
No
189
17.9
117
10.5
47
21.9
142
16.8
Yes
869
82.1
1002
89.5
168
78.1
701
83.2
CD4
67.1
< 0.001
10.7
0.001
< 200
137
12.6
276
26.7
13
7.6
124
17.9
≥ 200
950
87.4
758
73.3
157
92.4
570
82.1
Tables 3 and 4 show the results of the univariate analysis of the association between biological variables (sex, age), sociodemographic factors (place of residence, years of schooling, hospital attended), life habits and clinical variables (history of contact with tuberculosis, body mass index (BMI), use of HAART, time on HAART, presence of AIDS, T-lymphocyte CD4 count) and the two outcomes studied, adherence to TST and TST reactivity.
Table 3
Univariate analysis of the association between biological and socio-economic variables and adherence to TST and TST reactivity, Recife 2007-2010
Univariate analysis of the association between habits and clinical variables with adherence to TST and TST reactivity, Recife 2007-2010
VARIABLES
NOT TAKING TST
TST ≥ 5 mm
OR (CI 95%)
P
OR (CI 95%)
P
Habits
Alcohol Consumption
Non-drinker
1.0
-
1.0
-
Drinker
0.95 (0.80-1.13)
0.591
1.35 (1.00-1.82)
0.048
Smoking
No
1.0
-
1.0
-
Yes
1.14 (0.96-1.34)
0.113
1.53 (1.13-2.07)
0.006
Marijuana Use
No
1.0
-
1.0
-
Yes
1.30 (1.08-1.56)
0.006
1.79 (1.30-2.46)
< 0.001
Crack use
No
1.0
-
1.0
-
Yes
1.64 (1.17-2.30)
0.004
3.30 (1.91-5.70)
< 0.001
Cocaine use
No
1.0
-
1.0
-
Yes
1.48(1.11-1.98)
0.008
1.83(1.11-3.01
< 0.001
Clinical variables
History of Contact with Tuberculosis
No
1.0
-
1.0
-
Yes
0.88(0.73-1.06
0.175
1.27(0.92-1.74
0.133
BMI
Not malnourished
1.0
-
1.0
-
Malnourished
1.72(1.27-2.31)
< 0.001
0.80(0.92-1.75)
0.492
On HAART
No
1.0
-
1.0
-
Yes
0.99(0.81-1.21)
0.918
0.68(0.48-0.95)
0.027
Time on HAART
Less than 1 year
1.0
-
1.0
-
One year or more
0.47(0.37-0.60)
< 0.001
1.32(0.83-2.20)
O.221
AIDS
No
1.0
-
1.0
-
Yes
1.86(1.45-2.39)
< 0.001
0.72(0.49-1.04)
0.087
CD4
< 200
1.0
-
1.0
-
≥ 200
0.52(0.41-0.65)
< 0.001
2.62(1.44-4.78)
0.002
Factors associated with not taking the TST remaining in the final model of the multivariate analysis were: being male, aged up to 39 years, place of residence (living in cities in the interior of the state), being attended at the HCP, being a crack user, less time on HAART, presence of AIDS and a CD4 count ≥ 200 (Table 5).
Table 5
Multivariate Final Models for Not Taking TST and for TST ≥ 5 mm, RECIFE, 2007 - 2010
The results of the second stage of the study showed that, of the 1,087 patients who took the TST, 20.4% (222) tested positive (TST ≥ 5 mm). The mean TST was 3.9 mm (min = 0; max = 48 mm). The prevalence of TST ≥ 5 mm was 21.6% among patients with CD4 ≥ 200 and 9.49% among patients with CD4 < 200 and this difference was statistically significant (p = 0.002).
The mean CD4 count was 447.2 cells/mm3 in the group of patients who did not react to the TST and 557.9 in the group who did react and this difference was statistically significant (p < 0.001).
In the final multivariate model the following factors were associated with a reactivity to the TST: place of residence (living in the Metropolitan Region), being attended at the HCP, less than ten years of schooling, crack use and a CD4 count of ≥ 200 (Table 5).
Discussion
In the present study, 52.5% of patients did not take the TST, despite the fact that it is recommended by the Brazilian Ministry of Health. The non-adherence to TST was associated with being male, being younger, living in the interior of state of Pernambuco, being attended at the HCP, being a user of crack, less time on HAART, presence of AIDS and a CD4 count < 200. Among the patients who took the TST, 20.4% (222) tested positive (TST ≥ 5 mm). TST positivity was associated with crack use, CD4 ≥ 200, being attended at the HCP, having less years of schooling and living in the Metropolitan Region of the state of Pernambuco.
Reports on TST adherence have varied from a rate of 30%, for not taking the test in a country with a low prevalence of tuberculosis [28], and a rate similar to that encountered in the present study (50.2%) from a study also carried out in Brazil [45].
It was observed that the incorporation of the TST into routine care at the two centers was not sufficient to ensure that attending physicians actually requested the test, or indeed that patients would take it, even after talks had been given to raise the awareness of professionals and patients alike on the need and pertinence of the TST for recommending LTBI treatment. This situation contradicts the interpretation of some authors that the low rate of testing is a consequence of the unavailability of TST at health care services attending patients with HIV/AIDS [4, 27, 41]. It is important to clarify this question, since the treatment of LTBI depends essentially on the administration of the TST [41, 42, 45–47], and in Brazil this is recognized as an indicator of the quality of the service [41].
A recent WHO guideline recommends that in resource-limited countries the TST might not be required for starting LTBI treatment for people living with HIV, since screening for active TB has been carried out [48]. However, the Brazilian Ministry of Health does not adopt the criterion of performing LTBI treatment for people living with HIV when a TST has not been performed or the result is unknown, based on the grounds that the benefit is greater for those with TST reactor (≥ 5 mm), as demonstrated by a systematic review [31]. The exceptions are cases of people living with HIV that relate a history of recent contact (less than two years) with TB bacillus, or those who present radiographic imaging of sequelae of pulmonary TB with no previous history of TB treatment [42, 44].
The levels of adherence to TST in this study are of considerable concern, since a prevalence of TST ≥ 5 mm of 20.5% was encountered among those who took the test. This rate of reactivity must be related to the fact that patients live in a region with a high prevalence of TB. Pernambuco has an incidence coefficient of 47.6 per 100,000 inhabitants for tuberculosis and this is considered to be the highest in the Northeast region. Recife, the city where this study was developed is the Brazilian capital with the largest rates of new tuberculosis cases in the country (132 cases per 100,000 inhabitants) and the TB mortality rate was the greatest in the country, 7.7 per 100,000 inhabitants [46].
Two other studies carried out in Brazil found a prevalence of 24.8% [45] and 34.0% [17] for a positive reaction to the TST in HIV-positive individuals. At present in Brazil, around 50 million individuals are infected with M. tuberculosis and roughly 14% of tuberculosis cases are related to HIV [49]. This may explain the high rates for positive TST results. A lower prevalence has been reported in Atlanta (2.5%) and in Switzerland (9.4%), which lie in regions considered to have a low prevalence of tuberculosis [28, 50]. Moreover, a percentage of 20.5 of TST positivity would suggest that of the 1203 individuals who did not take the TST, around 20% could also be positive. Therefore, it is possible to estimate that 245 patients lost the opportunity of being diagnosed with and treated for LTBI. Furthermore, considering that among the 222 patients with positive TST results, 21 (9.5%) have been diagnosed with active tuberculosis, it is possible to estimate that around 23 patients could have been diagnosed and treated for active TB.
The final multivariate model of factors associated with not taking the TST showed that men and younger people presented a 48% and 28% greater likelihood of not taking the test, respectively. This would mean that adherence to the TST was less frequent among those with a greater likelihood of developing of tuberculosis [30, 31].
Of the life habits, only crack use remained in the final multivariate model, which is in accordance with the hypothesis that drug use impedes adherence to health care procedures. As expected, fewer people living in the interior of the state took the TST, possibly due to the distances between their homes and the health centers, which are located in the state capital, Recife. Not undergoing the TST was also associated to the diagnosis of AIDS, to less than one year on HAART and a CD4 count ≥ 200. Elzi et al. (2007) also found that the TST was performed more frequently among patients with CD4+ cell counts of < 200 cells/mL [28]. This would suggest that the more severe patients are more frequently tested for LTBI. The most aggravating factor within this group of patients is that they have a greater chance of having a non-reactive response to TST, even when present. Mycobacteriumtuberculosis is an intracellular pathogen that principally inhabits the macrophages. Protective immunity from M. tuberculosis depends on the integrity of the cellular immune system. HIV infection, by damaging the immunity mediated by cells, is the most potent known risk faction for reactivation of latent TB [3]. However, it is often not possible to detect this infection using the TST and some authors consider a negative TST in an HIV-positive patient with immunodeficiency to be a false negative [51–53]. The main implication of this is that treatment of LTBI is jeopardized in patients with a non-reactive TST caused by immunodeficiency. It is thus recommended that other factors be taken into account, such as the rate of infection or disease in the community, demographic data, a history of exposure and abnormalities in the chest X-ray [42]. These factors could help to identify patients with a high risk of developing tuberculosis, for whom LTBI treatment should be considered regardless of the TST result, given that there is as yet no valid substitute for the TST in patients with HIV [54].
One striking finding of the present study is the fact that the frequency of TST was different at the two centers (p < 0.001). This suggests different levels of involvement with TB control for the two teams. In particular, it stresses the role of the attending physician in this process, as it is this member of the team who, in Brazil, decides whether to initiate treatment of LTBI or not [23], and who is thus responsible for encouraging patients to take the TST when recommended. However, attention should be drawn to the nurses' role who is generally the team member that administers the TST, and who schedules the return visit to read the test.
According to the literature, a fundamental question relating to the control of HIV/tuberculosis co-infection is a higher degree of interaction between the action taken to control the two diseases, as a way of achieving a higher level of adherence on the part of patients to screening for tuberculosis and the treatments available [55]. This should extend beyond program coordination and include point of health care delivery, where a multidisciplinary team should be present to carry out tuberculosis control activities when caring for patients with HIV/AIDS.
The involvement of a multidisciplinary team is fundamental for the adequate running of a service, with each component playing a specific role. A study conducted among patients being attended at an adult emergency unit, including those living with HIV, has shown that triage, counseling and patient education are of special importance [56]. According to this study, it was counseling that took up most of the time, reaching out not only to patients, but also to family members and partners. Tuberculosis counseling also involved the provision of information on tuberculosis and HIV, and special attention was paid to making appointments, calling patients and ensuring patients pay a return visit by giving them a free bus ticket. Chaisson and colleagues [57] have emphasized the importance of the nurses' role, noting an increase in adherence to TST from 37% to 74%, when, in addition to a food vouchers, patients were offered a consultation with a nurse. This study also emphasized the importance of having a medical assistant involved in the final interpretation and progress of each case.
The present study has certain limitations due to its design (cross-sectional), which may have caused some associations due to reverse causality. Besides this, we had to deal with the difficulties of an operational research undertaken during the routine care of patients. A selection bias can have occurred due to the difficulties involved in accessing health services. However, health care for people living with HIV in Brazil is good and in spite of working with a convenience sample of patients being attended at two separate health centers, the sample size was robust enough to detect the differences between the groups.
Read phonetically
Furthermore, the findings of this study may contribute to a better understanding of the reasons why TB is the leading cause of death amongst people living with HIV in Brazil. Preventing TB in people living with HIV is one of the biggest challenges in countries with a reasonable prevalence of co-infected individuals.
Conclusions
Considering that the TST is recommended by the Brazilian health authorities, the coverage for taking the test TST was low. The most serious implication of this is that the treatment for LTBI was carried out for the unidentified TST-positive patients who may consequently go on to develop TB, and eventually die. It would be of great importance to review decisions regarding the initiation of LTBI treatment being conditional on the tuberculin skin test.
Declarations
Acknowledgements
This study received support from the Brazilian Ministry of Health/STD/AIDS/UNESCO Program (CSV 182/06 - Project "A Clinical and Epidemiological Study of HIV/Tuberculosis Co-infection in Recife"). The authors received partial support from the Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq (scholarship 301779/2009-0 to M.F.P.M. and 300917/2006-6 to R.A.A.X.) and the Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco - FACEPE (scholarship IBPG-0898-4.06/08 to J.D.L.B.).
Authors’ Affiliations
(1)
Department of Tropical Medicine, Universidade Federal de Pernambuco
(2)
Department of Medical Science, Universidade de Pernambuco
(3)
NESC Department, Centro de Pesquisas Aggeu Magalhães/FIOCRUZ
References
Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC: Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001, 15: 2137-47. 10.1097/00002030-200111090-00009.View ArticlePubMedGoogle Scholar
Corbett EI, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C: The Growing burden of tuberculosis. Arch Intern Med. 2003, 163: 1009-21. 10.1001/archinte.163.9.1009.View ArticlePubMedGoogle Scholar
McShane H: Co-infection with HIV and TB: double trouble. Intern J of STD & AIDS. 2005, 16: 95-101. 10.1258/0956462053057576.View ArticleGoogle Scholar
Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De cock KM, Hayes RJ, Churchyard GJ: Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. A novel randomized incremental recruitment study. JAMA. 2005, 293 (22): 2719-25. 10.1001/jama.293.22.2719.View ArticlePubMedGoogle Scholar
Lienhardt C, Cobelens FGJ: Operational research for improved tuberculosis control: the scope, the needs and the way forward. Int J Tuberc Lung Dis. 2011, 15 (1): 6-13.PubMedGoogle Scholar
Churchyard GJ, Scano F, Grant AD, Chaisson RE: Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. The J of Infec Dis. 2007, 196: 552-62.View ArticleGoogle Scholar
Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, Mcintyre J, Belcker LG: Undiagnosed tuberculosis in a community with high HIV prevalence. Implications for tuberculosis control. Am J of Respir and Crit Care Med. 2007, 175: 87-93.View ArticleGoogle Scholar
Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP, Pilotto JH, Cardoso SW, Keruly JC, Moore RD: Early mortality and cause of deaths in patients using HAART in Brazil and United States. AIDS. 2009, 23: 1-7. 10.1097/QAD.0b013e3283217f63.View ArticleGoogle Scholar
Mayer KH, Hamilton CD: Synergistic pandemics: confronting the global HIV and tuberculosis epidemics. CID. 2010, 50 (3): 567-70.Google Scholar
Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, Ippolito G, GISTA: Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000, 14: 1985-91. 10.1097/00002030-200009080-00015.View ArticlePubMedGoogle Scholar
Hsieh SM, Hung CC, Pan SC, Wang JT, Tsai HC, Chen MY, Chang SC: Restoration of cellular immunity against tuberculosis in patients co-infected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation. J Acquir Immune Defic Syndr. 2000, 25: 212-20. 10.1097/00126334-200011010-00002.View ArticlePubMedGoogle Scholar
Girard E, Palmiere F, Zaccarelli M, Tozzi V, Trotta MP, Selva C, Narciso P, Petrosillo N, Antinori A, Ippolito G: High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. AIDS. 2002, 16 (14): 1976-9. 10.1097/00002030-200209270-00021.View ArticleGoogle Scholar
Lawn SD, Bekker LG, Wood R: How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005, 19: 1113-24. 10.1097/01.aids.0000176211.08581.5a.View ArticlePubMedGoogle Scholar
Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV cohort study. JAMA. 1999, 282: 2220-6. 10.1001/jama.282.23.2220.View ArticlePubMedGoogle Scholar
Jones JL, Hanson DL, Dworkin MS, De Cock KM: HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Int J Tuberc Lung Dis. 2000, 4: 1026-31.PubMedGoogle Scholar
Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM: Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Austrália. JAIDS J Acquir Immune Defic Syndr. 2002, 29: 388-95.View ArticlePubMedGoogle Scholar
Santoro-Lopes G, Pinho AMF, Harrison LH, Schechter M: Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. CID. 2002, 34: 543-6. 10.1086/338641.View ArticleGoogle Scholar
Williams BG, Dye C: Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003, 301: 1535-7. 10.1126/science.1086845.View ArticlePubMedGoogle Scholar
Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Martinez PAS, Zapata MR, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch: Evaluación de dos pautas de quimioprofilaxis tuberculoa em pacientes infectdos por el vírus de la inmunodeficiência humana. Medicina Clínica. 2000, 115: 161-5.View ArticleGoogle Scholar
Casado JL, Moreno S, Fortin J, Antela A, Quereda C, Navas E, Moreno A, Dronda F: Risk factors for development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus-Infected Patients. CID. 2002, 34: 386-9. 10.1086/324746.View ArticleGoogle Scholar
Halsey NA, Coberly JS, Desoumeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE: Randomised trai of isosiazid versus rifampicin and pyrazinamide for of tuberculosis in HIV-1 infection. The lancet. 1998, 351: 786-792. 10.1016/S0140-6736(97)06532-X.View ArticleGoogle Scholar
Mwinga A, Hops M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KPWJ, Poeter JDH, et al: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998, l2: 2447-2457.View ArticleGoogle Scholar
Pinho AMF, Santoro-Lopes G, Harrison LH, Schechter M: Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS. 2001, 15: 2129-35. 10.1097/00002030-200111090-00008.View ArticlePubMedGoogle Scholar
Rivero A, López-Cortés L, Castillo R, Verdejo J, Garcia MA, Martinez-Marcos FJ, Diez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernandez JJ, Marquez M, Kindelán JM: Grupo Andaluz para el studio de las enfermedades infecciosas. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin. 2007, 25 (5): 305-10. 10.1157/13102265.View ArticlePubMedGoogle Scholar
Rivero A, Lópes-Cortez L, Castillo R, Lozano F, Garcia MA, Diez F, Escribano JC, Canueto J, Pasquau J, Hernandez JJ, Polo R, Martínez-Marcos FJ, Kindelán JM, Rey R: Grupo Andaluz para el studio de las enfermedades infecciosas. A randomized Trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy. Enferm Infecc Microbiol Clin. 2003, 21 (6): 287-292. 10.1157/13048575.View ArticlePubMedGoogle Scholar
World Health Organization: Stop TB department and department of HIV/AIDS. Interim Policy on collaborative TB/HIV activities. 2004, GenevaGoogle Scholar
World Health Organization, Global tuberculosis programme and UNAIDS: Policy statement on preventive therapy against tuberculosis in people living with HIV. Report of a meeting held in Geneva 18-20 February 1998. 1998, GenevaGoogle Scholar
Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H, The Swiss HIV Cohort Study: Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. CID. 2007, 44: 94-102. 10.1086/510080.View ArticleGoogle Scholar
Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. The New Engl J Med. 1997, 12: 801-8.View ArticleGoogle Scholar
Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD: Effect of isoniazida prophylaxis on incidence of active tuberculosis and progression of HIV infection. The Lancet. 1993, 31: 268-72.View ArticleGoogle Scholar
Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews. 2010, CD000171-1Google Scholar
American Thoracic Society/Centers for Disease Control and Prevention: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000, 161: 5221-47.Google Scholar
British Thoracic Society, Joint tuberculosis committee of British thoracic society: Control and prevention of tuberculosis in United Kingdom: code of practice 2000. THORAX. 2000, 55: 887-901. 10.1136/thorax.55.11.887.View ArticleGoogle Scholar
Tupasi TE, Radhakrishna S, Pascual MLD, Quelapio MI, Villa ML, Co VM, Sarol J, Mangubat N, Reyes AC, Sarmiento A, Solon M, Solon F, Burton L, Lofranco VS, Rostrata MPC, Mantala MJ: BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the nationwide prevalence surveys. Int J Tuberc Lung Dis. 2000, 4: 216-22.PubMedGoogle Scholar
Zhang LX, Tu DH, He GX, Ma ZQ, Nagelkerke NJ, Borgdorff MW, Enarson DA, Broekmans JF: Risk of tuberculosis infection an tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing. Am J Respir Crit Care Med. 2000, 162: 1314-7.View ArticlePubMedGoogle Scholar
Pablos-Mendes A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Weezenbeek CSB, Kim SJ, Chaulet P, Nunn P: Global surveillance for antituberculosis-drug resistance. N Engl J Med. 1998, 338: 1641-9. 10.1056/NEJM199806043382301.View ArticleGoogle Scholar
Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJC, Churchyard GJ, Grant AD: Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010, 24: 1-5. 10.1097/QAD.0b013e328333acfb.View ArticleGoogle Scholar
Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for preventing tuberculosis in non-HIV infected persons (cochrane review). The cochrane library. 2008, Oxford. Update software, 2Google Scholar
Woldehanna S, Volmik J: Treatment of latent tuberculosis infection in HIV infected persons (cochrane review). The cochrane library. 2006, Oxford. Update software, 1Google Scholar
Dodd PJ, Millington KA, Ghani AC, Mutsvangwa , Butterworth AE, Lalvani A, Corbett EL: Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. Am J Epidemiol. 2010, 171: 1037-45. 10.1093/aje/kwq017.View ArticlePubMedPubMed CentralGoogle Scholar
Jamal FF, Moherdaui F: Tuberculose e infecção pelo HIV no Brasil: magnitude do problema e estratégias para o controle. Rev Saúde Pública. 2007, 41 (1): 104-10.View ArticlePubMedGoogle Scholar
Brasil, Ministério da Saúde, Secretaria de Vigilância Sanitária: Tuberculose. Guia de vigilância epidemiológica. 2009, BrasíliaGoogle Scholar
Conde MB, Melo FAF, Marques AMC, Cardoso NC, Pinheiro VGF, Dalcin PTR, et al: III Diretrizes para tuberculose da sociedade brasileira de pneumatologia e tisiologia. J Bras Pneumol. 2009, 35 (10): 1018-48.View ArticlePubMedGoogle Scholar
Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde: Programa Nacional de DST e Aids. Guia de tratamento. Recomendações para terapia anti-retroviral em adultos infectados pelo HIV. 2008, BrasíliaGoogle Scholar
Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B: The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brasil. AIDS. 2007, 21: 1441-48. 10.1097/QAD.0b013e328216f441.View ArticlePubMedPubMed CentralGoogle Scholar
Nuwaha F: Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-saharan Africa. East African Med J. 1998, 9 (75): 520-7.Google Scholar
Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA: Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing center. AIDS. 1995, 9: 267-73.View ArticlePubMedGoogle Scholar
World Health Organization: Guidelines for intensified tuberculosis case finding and isoniazida preventive therapy for people living with HIV in resource constrained settings. Stop TB department and department of HIV/AIDS. 2011, Geneva WHOGoogle Scholar
Brasil, Ministério da, Saúde, DATASUS/MS/SUS: Tuberculose-Casos confirmados notificados no Sistema de informação de Agravos de Notificação-SINAN. Accessed march 25, 2010., [http://www2.datasus.gov.br/DATASUS/index.php?area=01]
Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM: Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infectious Diseases. 2009, 9: 15-24. 10.1186/1471-2334-9-15.View ArticlePubMedPubMed CentralGoogle Scholar
Garcia-Garcia ML, Valdespino-Gomez JL, Garcia-Sancho C, Mayar-Maya ME, Palácios-Martinez M, Balandrano-Campos S, Escobar-Guitiérrez A, Peruga A, Weissenbacher M, Daniels E: Underestimation of Mycobacterium tuberculosis infection in HIV-infected subjects using reactivity to tuberculin and anergy panel. Int J Epidemiol. 2000, 29: 369-75. 10.1093/ije/29.2.369.View ArticlePubMedGoogle Scholar
Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E: CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006, 42: 464-9. 10.1097/01.qai.0000225729.79610.b7.View ArticlePubMedGoogle Scholar
Wood R, Maartens G, Lombard CJ: Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000, 23: 75-80.View ArticlePubMedGoogle Scholar
Padmapriyadarsini C, Swaminathan S: Preventive therapy for tuberculosis in HIV infected individuals. Indian J Med Res. 2005, 121: 415-23.PubMedGoogle Scholar
Long R, Houston S, Hershfield E: Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. CMAJ. 2003, 169: 789-91.PubMedPubMed CentralGoogle Scholar
Kirsh TD, Chanmugam A, Keyl P, Regan LA, Sharan J, Hexter DA, Kelen GD: Feasibility of an emergency department-based tuberculosis counseling and screening program. Acad Emerg Med. 1999, 6: 224-31. 10.1111/j.1553-2712.1999.tb00161.x.View ArticleGoogle Scholar
Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD: Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 11 (5): 455-9. 10.1097/00042560-199604150-00005.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
